Anti-CD30 Antibodies for Hodgkin lymphoma

Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y.

Abstract

Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts to modify anti-CD30 antibodies to improve binding of effector cells and enhance activity appears more promising, as does the development of novel antibody-drug conjugates (ADCs). ADCs offer the potential to deliver potent therapies with minimal toxicity. One highly active ADC, brentuximab vedotin (SGN-35), combines an anti-CD30 monoclonal antibody and the antitubulin agent monomethyl auristatin E. Initial phase 1 studies of brentuximab vedotin showed a 52% overall response rate in relapsed HL, with minimal toxicity. This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Brentuximab Vedotin
  • Clinical Trials as Topic
  • Hodgkin Disease / drug therapy*
  • Humans
  • Immunoconjugates / therapeutic use
  • Immunotherapy
  • Ki-1 Antigen / immunology*
  • Oligopeptides / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunoconjugates
  • Ki-1 Antigen
  • Oligopeptides
  • Brentuximab Vedotin
  • monomethyl auristatin E